Elsevier

Biochemical Pharmacology

Volume 47, Issue 2, 20 January 1994, Pages 295-302
Biochemical Pharmacology

New sulfonated distamycin a derivatives with bFGF complexing activity

https://doi.org/10.1016/0006-2952(94)90020-5Get rights and content

Abstract

Tumor-induced neoangiogenesis is an essential event for solid tumor growth. Therefore, a compound able to block angiogenesis-promoting factors could have antitumor activity. The polysulfonated naphthylurea suramin is hypothesized to have this mode of action. A series of sulfonated distamycin A derivatives have been synthesized with the objective of identifying novel compounds able to complex basic fibroblastic growth factor (bFGF) and other factors involved in tumour angiogenesis, and consequently to block the angiogenic process. These new compounds have been characterized for their ability to inhibit bFGF binding, in vivo bFGF-induced angiogenesis and neovascularization of the chorioallantoic membrane, in comparison with suramin. The two most active compounds, FCE 26644 [7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis (1,3-naphthalenedisulfonic acid)] and FCE 27164 [7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino N-methyl-4,2-pyrrole) carbonylimino)-bis (1,3,5-naphthalenetrisulfonic arid)] have been selected for extended evaluation. Both compounds are active in inhibiting platelet-derived growth factor β (PDGFβ) and interleukin-1β binding. Two different assays have been performed to study their mode of action: the sequential binding assay on bFGF and PDGF receptors and the bFGF-induced tyrosine phosphorylation assay. The results of the two assays are in agreement and indicate that no activity is observed if FCE 26644, FCE 27164 and suramin are administered as pretreatment, when a direct interaction of the compounds with bFGF and PDGF receptors is required. Conversely, inhibitory activity is observed when the compounds are allowed to form complexes with the growth factors themselves.

References (34)

  • CE Myers et al.

    Treatment of hormonally refractory prostate cancer with suramin

  • RV La Rocca et al.

    Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy

  • K Ono et al.

    Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin

    EurJ Biochem

    (1988)
  • Y Moriyama et al.

    Inhibition of vacuolar H+ ATPases by fusidic acid and suramin

    FEBS Lett

    (1988)
  • SJ Butler et al.

    Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin sensitive guanine-nucleotide-binding proteins

    Biochem J

    (1988)
  • RJ Coffey et al.

    Suramin inhibition of growth factor receptor binding and mitogenicity in ARK-2B cells

    J Cell Physiol

    (1987)
  • M Hosang

    Suramin binds to platelet-derived growth factor and inhibits its biological activity

    J Cell Biochem

    (1985)
  • Cited by (52)

    • DNA minor groove binders: Back in the groove

      2009, Cancer Treatment Reviews
      Citation Excerpt :

      The next clinically relevant derivative of distamycin to enter development was the drug PNU-145156E, previously named FCE 26644. Though derived from the DNA binding distamycin backbone, initial experiments revealed that the primary method of action of this drug and similar agents was the binding of basic fibroblast growth factor, a pleiotropic cytokine important in angiogenesis.22 Despite apparent lack of cytotoxcity on its own, PNU-145156E showed combinatorial efficacy with other cytotoxic drugs23 and entered phase I trials.

    • Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino [N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding

      2002, Biophysical Journal
      Citation Excerpt :

      Since the demonstration of the role of angiogenesis in cancer, the search for angiogenesis inhibitors has become the focus of several research groups (Herblin et al., 1994; Auerbach and Auerbach, 1994). In the last few years, naphthalene sulfonic distamycin-A derivatives were shown to inhibit the binding of human recombinant bFGF to its receptors, to block in vivo bFGF-induced vascularization and to stop neovascularization in chorioallantoic membrane (Ciomei et al., 1993). Suramin is one such polysulfonated naphthylurea that was examined as a potential anticancer drug (La Rocca et al., 1990; Kohler et al., 1992; Braddock et al., 1994; Manetti et al., 1998, 2000).

    View all citing articles on Scopus
    View full text